Revenue in the third quarter amounted to 158.5 MSEK, representing growth of 15.3%

Revenue amounted to 158.5 (137.5) MSEK in the third quarter, representing growth of 15,3%. Adjusted EBITDA amounted to 43.7 (32.6) MSEK, representing growth of 34.0%. Cambio acquired 100% of the shares in MittVaccin, a Swedish company within the vaccination record business. Revenue during January - September amounted to 518.8 (20 Feb - 30 Sep, 2019; 334.7) MSEK. Adjusted EBITDA amounted to 143.9 (20 Feb -30 Sep 2019; 67.1) MSEK

Comments from Peter Gille, CEO

As a result of the spread of the Corona virus many people are living with challenging conditions and many have lost their lives. Cambio’s most important task under the current circumstances is to ensure our products fulfil their purpose without any interruptions and enable doctors and nurses to spend more time focusing on critical patients.

The impact of Covid-19 on society and businesses continues to be severe. Cambio’s priorities under the current circumstances are to support our customers, to ensure our products fulfil their purpose without any interruptions and to protect the health and safety of our employees. Cambio has, together with our existing customers, taken actions to directly address Covid-19 effects with our software to make it possible to decrease administrative time, share information with municipalities and provide more intensive care beds.

Direct interactions with our customers remain on a low level making it harder to sell new projects and obtain delivery approvals. This has impacted project timings and therefore revenue recognition in the third quarter. We have also seen some impact on our operational efficiency and productivity. With the spread of Covid-19 accelerating in the beginning of the fourth quarter we anticipate further and potentially larger impacts on the timing of projects during the remainder of the year.In the third quarter, Cambio continued to deliver on its M&A strategy acquiring MittVaccin. Through the acquisition, Cambio gains the potential to fill an upcoming gap for a nationwide vaccination solution. MittVaccin also adds to Cambio’s revenues and provides for a product with international appeal. This is the second acquisition in two consecutive years, through which Cambio´s product portfolio is broadened and in line with the interests and requirements of Cambio´s customer base.  

Please find the report here. For more information from Cambio, please visit cambiogroup.com.

This information is information that Sanolium AB(publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 10 am CEST on 27 November 2020.

For further information, please contact: 

Fredrik Rüden, CFO +46 8 691 49 00 fredrik.ruden@cambio.se

JennyStyren, CMCO +46 8 691 49 00 jenny.styren@cambio.se

SanoliumAB is the parent company in the CambioGroup, since February 20, 2019. The largest operating subsidiary in that group is Cambio Healthcare Systems whichwas founded in 1993 to deliver comprehensive IT-solutions for healthcare organizations. Today, Cambio is an e-health company providing smart, reliable, and user-friendly solutions to improve healthcare and patient safety with a market leading position in the Nordics including more than 100 000 users. We are committed to improve healthcare and patient safety